Dupilumab Linked to Food Challenge Reactions in Study

A study found pediatric patients had higher reaction rates during food challenges after using the drug dupilumab.

Updated on Sept. 30, 2026 in Allergies

A close-up of a glass pipette over a sterile laboratory petri dish. — A new study indicates that pediatric patients taking dupilumab experienced increased allergic reaction rates during oral food challenges, challenging previous clinical assumptions about blood marker correlations. AI Illustration. Upload story photo >

Live Poll

Do you trust medical lab results when they contradict a patient's physical symptoms or reactions?

Researchers reviewing medical records through November 2024 found that pediatric patients experienced increased reaction rates during oral food challenges following dupilumab treatment. The study, published on September 24, 2026, suggests significant changes in clinical outcomes despite a decline in IgE levels.

Why it matters

Understanding the discrepancy between lowered blood markers and clinical reactions is essential for clinicians managing severe food allergies. This analysis challenges assumptions that reduced food-specific IgE levels automatically correlate with improved tolerance to allergens in children.

The study included 129 pediatric patients with a median age of 13 years and a median dupilumab treatment duration of 25 months. Food-specific IgE levels declined by 49% to 89% from baseline following the therapy.

The players

The Journal of Allergy and Clinical Immunology

This is a peer-reviewed medical publication that focuses on the research and clinical aspects of allergic and immunologic diseases.

The details

The retrospective review included 107 oral food challenges conducted on pediatric patients treated at a Chicago-based institution. Data showed that dupilumab exposure was linked to a threefold increase in the odds of higher severity scores on both the SGSAR and Bock/PRACTALL scales.

Retrospective patient records were reviewed from November 2014 through November 2024.
The findings were published in The Journal of Allergy and Clinical Immunology on September 24, 2026.

The Big Picture

This research shifts the trajectory of allergy treatment by highlighting an unexpected clinical outcome in pediatric biologic therapy. It updates the long-standing medical assumption that decreased immunoglobulin levels serve as a sufficient proxy for successful allergen desensitization.

Families and clinicians should be aware that dupilumab treatment may not equate to immediate tolerance when introducing allergenic foods. Patients undergoing such therapy may require adjusted safety expectations and closer medical supervision during oral food challenges.

The takeaway

Clinicians must prioritize clinical observation over blood tests when assessing an allergic patient's reaction risk after biologic therapy. Relying solely on IgE reduction can lead to dangerous underestimations of a child's sensitivity to allergens.